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Abstract
The most effective strategy for preventing influenza is annual vaccination. We analyzed data from 
the 2005-2011 National Health Interview Survey (NHIS) using the Kaplan-Meier survival analysis 
procedure to estimate the cumulative proportion of persons reporting vaccination in the 2004-05 
through 2010-11 seasons for persons ≥18, 18-49, 50-64, ≥65, persons with high-risk conditions, 
and health care personnel. We compared vaccination coverage by race/ethnicity within each age 
and high-risk group. Vaccination coverage among adults ≥18 years increased from 27.4% in the 
2005-06 season to 38.1% in the 2010-11 season, with an average increase of 2.2% annually. From 
the 2005-06 to the 2010-11 seasons, coverage increased by 10-12 percentage points for all groups 
analyzed except for adults aged ≥65 years. Coverage for the 2010-11 season was 70.2% for adults 
≥65 years, 43.7% for 50-64 years, 36.7% for 18-49 years with high-risk conditions, and 55.8% for 
health care personnel. Coverage in the 2010-11 season was significantly lower among non-
Hispanic blacks and Hispanics compared with non-Hispanic whites among most of the adult sub-
groups. Vaccination coverage among adults <65 years increased from the 2005-06 through the 
2010-11 seasons, but substantial racial and ethnic disparities remained in most age groups. 
Targeted efforts are needed to improve coverage and reduce disparities.
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Introduction
Influenza is a major cause of morbidity and mortality among adults in the United States 
(1-4). Annual epidemics of influenza typically occur during the late fall through early spring 
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in the United States. Influenza viruses cause disease among persons in all age groups (1). 
Rates of serious illness and death are higher among adults aged ≥65 years, children younger 
than 2 years, pregnant women, and persons of any age who have medical conditions that 
place them at increased risk for complications from influenza (1). Influenza illness burden 
among healthy adults 18-49 years is an important cause of outpatient medical visits and loss 
of work days (5-6). Influenza vaccination has been shown to be a cost-effective tool for 
reducing morbidity and mortality associated with influenza among adults (5, 7-18). The 
economic impact of influenza illness is substantial. One national study estimated the annual 
economic burden of seasonal influenza in the United States to be $87.1 billion, including 
$10.4 billion in direct medical costs (6).
Since the 2010-11 influenza season, the Advisory Committee on Immunization Practices has 
recommended annual influenza vaccination for all persons 6 months of age and older. Prior 
to 2010, the adult groups recommended for annual vaccination included persons 50 years 
and older, pregnant women, persons aged 18-49 years with medical conditions associated 
with higher risk of complications from influenza infection, health care personnel, and close 
contacts of high risk persons (19). Healthy adults aged 18-49 years who were not close 
contacts of persons at high risk were added to those recommended for annual vaccination 
beginning in the 2010-11 season and the recommendation for adults aged 18-49 years was 
the major change in recommendations during the study period (1).
The most effective strategy for preventing influenza is annual vaccination. However, 
vaccination coverage has been suboptimal (1, 20-27). To assess the impact of the current 
adult influenza vaccination program in the United States and to identify strategies to 
improve vaccination coverage among adults, we analyzed the data from the 2005-2012 
National Health Interview Survey (NHIS). We assessed influenza vaccination coverage 
among adults by age, high-risk status, and racial/ethnic groups.
Methods
We estimated national influenza vaccination coverage among U.S. adults using 2005-2011 
NHIS data, and preliminary, early release NHIS data from January-March 2012. The NHIS 
is a national cross-sectional household survey that is conducted by the Centers for Disease 
Control and Prevention (CDC) (26, 28). The survey samples civilian, non-institutionalized 
populations living in the United States at the time of the survey. Face-to-face interviews are 
conducted weekly throughout the year with a probability sample of households. The NHIS 
provides estimates of health indicators, health care utilization and access, and health-related 
behaviors, and minority racial/ethnic groups (black, Hispanic, and others) were oversampled 
to allow for more precise estimation of health characteristics in these growing minority 
populations (26, 28). Seasonal influenza vaccination status was assessed by asking 
respondents if they had a seasonal influenza vaccination during the past 12 months and what 
month and year vaccination was received.
We defined high-risk persons as individuals who self-reported one or more of the following: 
ever being told by a physician they had diabetes, emphysema, coronary heart disease, 
angina, heart attack or other heart condition; being diagnosed with cancer in the past 12 
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months (excluding non-melanoma skin cancer) or ever being told by a physician they have 
lymphoma, leukemia or blood cancer; during the past 12 months, being told by a physician 
they have chronic bronchitis or weak or failing kidneys; or reporting an asthma episode or 
attack in the past 12 months. Race/ethnicity is defined as individuals who identified 
themselves as non-Hispanic white, non-Hispanic black, Hispanic, and others (including 
Asian, American India/Alaska Native, and multiple races).
Although female respondents were asked if they were pregnant at the time of the interview, 
estimates of influenza vaccination among pregnant women were not assessed due to survey 
limitations. Because pregnancy status was determined at the time of interview, currently 
pregnant women who were not pregnant during the influenza season could not be 
distinguished from currently pregnant women who were pregnant during the influenza 
season, and women not pregnant at the time of the survey but pregnant during the influenza 
season could not be identified. Starting in 2012, the NHIS began collecting information on 
influenza vaccination before, during, and after a recent or current pregnancy. Other data 
sources that more specifically ascertain pregnancy status in relation to vaccination histories 
are available (29-31).
During the 2005-06 through 2008-09 seasons, individuals were classified as health care 
personnel (HCP) if they were currently employed in a health care occupation or in a health 
care industry setting, based on standard occupation and industry categories recoded into 
categories by the National Center for Health Statistics (NCHS) at CDC. Health occupation 
included health diagnosing occupations, health assessment and treating occupations, health 
technologists, and health service occupations. Health care settings included hospitals, 
nursing or personal care facilities, and offices of physicians, dentists, chiropractors, 
optometrists or other health care practitioners. The NCHS categories of HCP are described 
further in Walker et al (25). From the 2009-10 to 2010-11 seasons, HCP is defined as adults 
aged ≥18 years who reported they currently volunteer or work in a hospital, medical clinic, 
doctor's office, dentist's office, nursing home or some other health-care facility, including 
part-time and unpaid work in a health care facility as well as professional nursing care 
provided in the home. The new definition we used in the 2009-10 to 2010-11 seasons is 
comparable to the definition we used in the 2005-06 through 2008-09 seasons (the 
agreement rate is about 95% between these two HCP definitions based on the 2010-11 NHIS 
data).
SUDAAN (Software for the statistical analysis of corrected data, Research Triangle 
Institute, Research Triangle Park, NC, version 10.01) was used to calculate point estimates 
and 95% confidence intervals (CIs). We assessed influenza vaccination among adult 
populations and stratified by race/ethnicity. To better assess influenza vaccination coverage 
for each season, we reported coverage restricted to individuals interviewed during 
September through June, and vaccinated during August through May, using the Kaplan-
Meier survival analysis procedure. For example, respondents interviewed during September 
2010 through June 2011 were analyzed to estimate influenza vaccination received during 
August 2010 through May 2011. For the 2004-05 season, estimates are based on interviews 
conducted during January through June 2005, and vaccination received during August 2004 
through May 2005 (Starting from 2005, month and year of influenza vaccination was 
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included in the NHIS data), while for the preliminary 2011-12 season estimates, interviews 
from September 2011 through March 2012, and vaccination received during August 2011 
through February 2012 were used (interviews conducted during January through March 
2012 are based on the 2012 NHIS early released data). Vaccination status was determined 
using reported month and year of most recent vaccination as of the end of the month prior to 
interview. T tests for linear trends in recent years were conducted for each group (coverage 
in the 2004-05 season was excluded from trend analysis since vaccine shortage occurred in 
the 2004-05 season and coverage among each group were substantially low). Racial/ethnic 
differences within each target group were assessed with T tests. All analyses were weighted 
to reflect the age, sex, and race/ethnicity of the U.S. non-institutionalized, civilian 
population. All tests were 2-tailed with the significance level set at α<0.05. A new weight 
variable was created based on how many months of interview data were included in the 
analyses. Since we restricted to individuals interviewed during September through June for 
the 2005-06 through 2010-11 seasons and 10 months of interview data were included in the 
analyses, the new weight variable=final weight*(12/10), while for the 2004-05 season, new 
weight=final weight*(12/6), and for the 2011-12 season, new weight=final weight*(12/7).
Individuals who refused to answer the influenza vaccination question or did not know their 
vaccination status (about 1.6% per season) were excluded from the analysis. Vaccination 
status was imputed for individuals who said they received vaccination but did not report their 
month and year of vaccination (percentage points imputed ranged 3-5% during the 2004-05 
season through the 2011-12 season). Information was imputed from donor pools matched for 
week of interview, age group, region of residence, and race/ethnicity.
Results
Sample characteristics of the study population by age and high-risk status are given in Table 
1. Overall, in the 2004-05 through the 2011-12 seasons, the NHIS analytic sample size 
ranged from 14,798-25,758 adults.
Overall, for all age and high-risk groups, vaccination coverage was substantially lower for 
the 2004-05 season when a vaccine supply shortage occurred compared to the 2005-2006 
season (Table 2). Influenza vaccination coverage among adults aged ≥18 years, 18-64 years, 
18-49 years, and 50-64 years increased significantly from 27.4%, 20.0%, 15.2%, and 32.5%, 
respectively from the 2005-06 season to 38.1%, 31.5%, 26.1%, and 43.7%, respectively in 
the 2010-11 season, with annual average increases of 2.2%, 2.3%, 2.2%, and 2.3%, 
respectively (test for trend, p<0.05) (Table 2). The test for linear trend in vaccination 
coverage from the 2005-06 through 2010-11 seasons among adults aged ≥65 years was not 
statistically significant. Among adults aged ≥65 years, seasonal vaccination coverage during 
the 2009-10 season (66.5%) was significantly lower than coverage during the 2008-09 
(69.6%) and 2010-11 (70.2%) seasons (p<0.05) (Table 2, Figure).
Among adults with high-risk conditions, vaccination coverage for adults aged 18-64 years, 
18-49 years, and 50-64 years significantly increased from 33.9%, 24.7%, and 44.3%, 
respectively in the 2005-06 season to 45.6%, 36.7%, and 54.4%, respectively in the 2010-11 
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season, with annual average increases of 2.4%, 2.4%, and 2.1%, respectively (test for trend, 
p<0.05) (Table 2, Figure).
Among adults without high-risk conditions, vaccination coverage for adults aged 18-64 
years, 18-49 years, and 50-64 years significantly increased from 16.9%, 13.7%, and 27.2%, 
respectively in the 2005-06 season to 28.1%, 24.3%, and 38.8%, respectively in the 2010-11 
season (test for trend, p<0.05) (Table 2). For all years, within each age group, coverage was 
significantly lower among those without high-risk conditions compared with those with 
high-risk conditions (Table 2).
Among HCP, coverage significantly increased from the 2005-06 season to the 2010-11 
season, with an annual average increase of 2.5% (test for trend, p<0.05) (Table 2, Figure). 
Vaccination coverage for the 2009-10 and 2010-11 seasons among HCP were 60.3%, and 
55.8%, respectively (Figure, Table 2). For the 2010-11 season, influenza vaccination 
coverage among HCP was significantly lower for Hispanics and non-Hispanic blacks 
compared to non-Hispanic whites (Table 3).
Influenza vaccination coverage for the 2010-11 season by race and ethnicity, age group, and 
high risk status is shown in Table 3. Vaccination coverage among most adult sub-groups was 
significantly lower for Hispanics and non-Hispanic blacks compared with non-Hispanic 
whites (Table 3). Coverage for the 2010-11 season among adults 18-64 years with high-risk 
conditions was similar across racial/ethnic groups.
Preliminary vaccination coverage for the 2011-12 season is shown in the figure. Preliminary 
vaccination coverage estimates for the 2011-12 season were similar to the 2010-11 season 
estimates among age and high-risk groups, except for increase in coverage among HCP from 
55.8% (52.8, 58.9) in the 2010-11 season to 62.4% (58.3, 66.6) in the 2011-12 season.
Discussion
Our study indicates that influenza vaccination coverage among adults significantly increased 
over five influenza seasons through 2010-11, but varied by age group and whether 
respondents reported health conditions associated with risk for complications from influenza 
infection. Vaccination coverage among all groups recommended for vaccination remains 
suboptimal (including HCP). Coverage was lower than the 90% Healthy People 2020 target 
for persons 18-64 years with high-risk conditions, persons aged ≥65 years, and HCP (32). 
Vaccination coverage was substantially lower for all age and high-risk groups in the 2004-05 
season due to the vaccine supply shortage which occurred during that season (33).
Overall, by the 2010-11 season, the first season during which all adults were recommended 
for influenza vaccination, vaccination coverage among adults ≥18 years was 38% with 
vaccination estimates steadily increasing from the 2005-06 season through the 2010-2011 
season. Coverage also increased steadily from the 2005-06 season through the 2010-2011 
season among healthy adults aged 18-49 year, the group added in 2010 to those for whom 
annual vaccination is recommended by the Advisory Committee on Immunization Practices 
(1). This group was added given the known significant morbidity and economic impact of 
influenza in working age adults (12). In addition, the universal vaccination recommendation 
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also eliminates the need to determine whether each person has one or more specific 
indications for vaccination and emphasizes the importance of preventing influenza among 
persons of all ages (1). Continuing annual monitoring of vaccination coverage among adults 
≥18 years is important to assess the impact of the vaccination program and to focus efforts 
on groups with lagging coverage.
Influenza vaccination uptake remains low among adults for whom vaccination has long been 
recommended, especially adults younger than 65 years of age who have high-risk medical 
conditions. In the 2010-11 season, vaccination coverage among adults 18-64 years with 
high-risk conditions was only 45.6%. This is substantially lower than the 90% Healthy 
People 2020 target for this risk group. The universal influenza vaccination recommendation 
may help improve vaccination coverage among this age group in future seasons, but 
continued focus to ensure vaccination among high-risk groups is essential as they are at the 
greatest risk of influenza-related hospitalization and death (34, 35). Primary care physicians, 
medical subspecialists, and other health care professionals and vaccination providers, 
including pharmacists, should work together to ensure that persons at high-risk are assessed 
for their vaccine needs, receive a strong recommendation for vaccination and are either 
vaccinated by the recommending provider or referred to another provider if they do not 
provide influenza vaccination services.
Vaccination coverage for adults aged ≥65 years did not significantly increase linearly during 
the 2005-06 season (66.0%) through 2010-11 seasons (70.2%), and the preliminary estimate 
for 2011-12 was similar to 2010-11. The lack of change in influenza vaccination coverage in 
this age group indicates that new approaches are needed if increases in influenza vaccination 
are to occur and reach the 90% Healthy People 2020 target. Reasons for the lack of change 
in coverage are not well understood. One recent study indicated that the majority (67%) of 
adults aged ≥65 years who are vaccinated receive their influenza vaccination in a clinical 
setting, which is significantly higher than those aged 18-49 years (54%) and 50-64 years 
(56%) (36). One potential reason for the level coverage in recent years might be related to 
system or operational factors affecting the number of persons that can be vaccinated in 
clinical settings and the failure to implement interventions to promote immunization. An 
increase in vaccination in alternative settings (e.g., community immunizers, health 
department clinics, pharmacies, and educational settings) may help improve influenza 
vaccination; however, individuals must be motivated to seek out vaccination, and an increase 
in the proportion of older persons receiving influenza vaccinations in retail settings was not 
associated with an increase in vaccination coverage (36, 37). A provider's recommendation 
remains one of the most important determinants of vaccination (36, 37).
Trivalent seasonal influenza vaccination coverage declined during the 2009-10 season 
among adults aged ≥65 years. One of the possible reasons is that adults aged ≥65 were not in 
the first priority groups for limited doses of the influenza A (H1N1) 2009 monovalent 
vaccine, although they were included in targeted groups once vaccine supply increased (38). 
Lower coverage in older adults might reflect confusion regarding the influenza A (H1N1) 
2009 monovalent vaccine recommendations and the continued strong recommendation to 
vaccinate all elderly with seasonal influenza vaccine.
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Influenza vaccination coverage among HCP increased by twelve percentage points from the 
2005-06 through 2010-11 seasons, although a similar increase was observed for all adults 
aged 18-64 years. HCP are exposed to influenza both at work and in the community. 
Vaccination of this group is especially important given their exposure to many high risk 
patients and the fact that HCP often work while ill (39-42). Despite influenza vaccination 
being recommended annually for HCP by the Advisory Committee on Immunization 
Practices and numerous medical, nursing and pharmacy professional organizations, and 
being part of the Standards for Adult Immunization Practices (43), vaccination coverage 
remains suboptimal. Low awareness of the federal vaccination recommendations for 
seasonal influenza vaccination among HCP may have affected vaccination coverage. One 
study showed that only about 45-50% of HCP correctly reported being in the target groups 
recommended to receive annual influenza (Unpublished data, and CDC-sponsored 
population-based internet panel surveys in the 2010-11 influenza season). Factors that may 
increase vaccination coverage among HCP include convenient access to vaccination during 
all shifts and at no cost to HCP, health care facility leadership support for vaccination efforts, 
providing feedback to HCP on vaccination levels at their workplace, and education of HCP 
that emphasizes the importance of HCP vaccination for patient safety, the effectiveness and 
safety of influenza vaccine (44). Worksite vaccination could significantly increase seasonal 
vaccination coverage among HCP; however, one study showed that one-third of health care 
settings did not offer on-site vaccination for HCP (44).
Our study showed that vaccination coverage among most adult sub-groups that were 
analyzed was significantly higher among non-Hispanic white compared with non-Hispanic 
blacks and Hispanics. Racial/ethnic disparities in influenza vaccination have been described 
in previous studies (21, 23-26, 45). Multiple factors likely contribute to these racial/ethnic 
disparities, including differences in attitudes toward vaccination and preventive care, 
propensity to seek and accept vaccination, variations in likelihood that providers recommend 
vaccination, and differences in quality of care received by racial/ethnic populations (1, 24, 
25, 46-51). Broad use of interventions to remove barriers to access and to make offering of 
vaccination in health care and other settings a routine practice are important components of 
efforts to reduce these disparities (51, 52). Efforts to reduce disparities may be most 
important for older adult age groups given smaller disparities in adults aged 18-49 years.
The CDC publishes estimates of influenza vaccination coverage from several data sources, 
including the Behavioral Risk Factor Surveillance System (BRFSS), National Immunization 
Survey, internet panel surveys, and NHIS (29). For adults, the estimates from BRFSS 
provide timely national and state-specific estimates that are available by the time the next 
influenza vaccination campaigns begin. Internet panel surveys provide timely estimates (in-
season and rapid post-season) for the general population and rarer populations of HCP and 
pregnant women while also providing information on knowledge, attitudes and behaviors 
related to influenza vaccination. Estimates from NHIS are not as timely, but may provide 
more valid national estimates than estimates from telephone and internet panel surveys. The 
NHIS is a national household survey conducted mostly by face-to-face interviews with 
higher response rates (60-70%) than the BRFSS, a telephone survey with lower response 
rates (50-60%) (23, 26, 28, 53, 54). For assessing national trends, other advantages of NHIS 
include availability of a more complete set of high-risk conditions and longer availability to 
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provide season-specific estimates using self-reported month and year of most recent 
influenza vaccination (since 2005 for NHIS compared to 2008 for BRFSS).
Thus, the NHIS provides a means to assess the potential validity of estimates from more 
timely data sources. Influenza vaccination coverage in the 2010-11 season based on the 
BRFSS data was somewhat higher compared to NHIS estimates (40.5% vs. 38.1% for adults 
aged ≥18 years, 30.5% vs. 26.1% for adults aged 18-49 years, and 44.5% vs. 43.7 for adults 
aged 50-64 years), and lower for adults ≥65 years (66.6% from BRFSS vs. 70.2% from 
NHIS). While NHIS estimates for adults aged ≥65 years appear stable in recent seasons 
aside from a dip during 2009-10, BRFSS estimates for this age group appear to indicate a 
possible decline, with estimates of 74% for 2008-09, 67% for 2010-11, and 65% for 2011-12 
(53). However, both data sources indicate coverage in older adults is in the range of 65-70% 
with much room for improvement. Ongoing comparisons of NHIS and other sources of 
influenza vaccination coverage are needed; over several seasons, these comparisons will 
provide a better assessment of the validity of signals in trends and disparities identified from 
other data sources. Factors that may contribute to the differences in estimated vaccination 
coverage between NHIS and other data sources include more representative sample frame 
and higher response rates for NHIS, survey mode (in-person for NHIS, telephone or internet 
for others), and differences in survey operations and weighting procedures. Starting in 2008, 
BRFSS began adding samples of persons in households with only cellular telephone service 
in each state to the landline telephone sampling frame (55).
The findings in this report are subject to limitations. Influenza vaccination status and high-
risk conditions were self-reported and were not validated with medical records. However, 
self-reported seasonal influenza vaccination status among older adults has been shown to 
have relatively high agreement with vaccination status ascertained from medical records, 
with a range of a 5-11 percentage point higher estimates based on self-reported vaccination 
status compared to estimates based on vaccination status from medical records (56-58). For 
the 2009-10 season when both seasonal vaccine and the influenza A (H1N1) 2009 
monovalent vaccine were both available, it is possible that some persons may have confused 
receipt of the influenza A (H1N1) 2009 monovalent vaccination and seasonal influenza 
vaccination, with potential for over- or under-estimation of coverage for seasonal vaccine in 
2009-10. NHIS response rates were 60-70%, and it is possible that non-response bias may 
remain after weighting adjustments.
Influenza vaccination coverage in all groups recommended for vaccination remains 
suboptimal. Substantial improvement in annual influenza vaccination of recommended 
groups is needed to maximally reduce the health impact of influenza. Expanded access 
through greater use of complimentary settings and vaccine providers, and better use of 
evidence-based practices at medical sites (e.g., standing orders, and reminder/recall 
notification) are important to improve influenza vaccination coverage further (43).
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Figure 1. Influenza Vaccination Coverage Among Adult Populations, the 2004-2005 to 2011-2012 
Seasons
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